Trials / Completed
CompletedNCT00407537
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,531 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 35 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine besylate/atorvastatin calcium single pill combination | Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2006-12-05
- Last updated
- 2021-01-28
- Results posted
- 2011-11-11
Locations
125 sites across 20 countries: Costa Rica, Croatia, Czechia, Dominican Republic, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Mexico, Panama, Philippines, Russia, Saudi Arabia, South Korea, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, Venezuela
Source: ClinicalTrials.gov record NCT00407537. Inclusion in this directory is not an endorsement.